Axium Awarded Phase III Clinical Trial Management Contract for OxThera’s Oxabact™
Axium Healthcare Pharmacy announced today that it has been awarded the clinical trial management contract for OxThera’s Oxabact™. Oxabact™ is manufactured by OxThera.
Lake Mary, FL, January 09, 2008 --(PR.com)-- Axium Healthcare Pharmacy, one of the nation’s largest independent specialty pharmacy providers, announced today that it has been awarded the clinical trial management contract for OxThera’s Oxabact™. Oxabact™ is manufactured by OxThera.
Oxabact™ is a capsulated bacterium that requires frozen storage and strict refrigerated shipment monitoring. The indication for Oxabact™ is Primary Hyperoxaluria (PH), a rare pediatric genetic disease, which causes the liver to produce excess amounts of oxalate. The estimated U.S. population for PH is in the range of 1,000 patients.
Axium will be working in conjunction with OxThera and the Mayo Clinic in this Phase III clinical trial. “We are excited about the opportunity to be working with OxThera in the drug management of their Phase III clinical trial for Oxabact. It will also be an honor working on this project with the prestigious Mayo Clinic,” said Mark Montgomery, President & CEO of Axium.
Jon Heimer, President of OxThera, said, “OxThera is very excited about entering into Phase III studies with Oxabact™ in the U.S. and look forward to collaborating with Axium Healthcare Pharmacy for the important process of drug management.”
About Axium Healthcare Pharmacy:
Axium Healthcare Pharmacy, Inc. is a nationwide clinical specialty pharmacy provider with expertise in managing patients on complex therapies and specialty medication distribution. As one of the nation's leading specialty pharmacies, Axium Healthcare Pharmacy, Inc. provides comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, Growth Hormone Deficiency plus others. For more information, contact Axium Healthcare Pharmacy at 888.315.3395; by email info@axiumhealthcare.com
About OxThera:
OxThera is a clinical stage biotechnology company with its first product in Phase III. The company is based in Sweden (Uppsala) and Florida (Gainesville). The company develops products, based on its cell- and enzyme based proprietary technologies, for metabolic disorders based on excess oxalate from endogenous and exogenous sources. OxThera will market and sell its orphan drug products to treat and prevent hyperoxaluria and kidney stones in indications such as Primary and Enteric Hyperoxaluria. For more information, contact OxThera at (386) 418-1428; by email info@oxthera.com.
Contact: Valerie Thomas
Corporate Director of Marketing
(888) 315-3395
Valerie.thomas@axiumhealthcare.com
###
Oxabact™ is a capsulated bacterium that requires frozen storage and strict refrigerated shipment monitoring. The indication for Oxabact™ is Primary Hyperoxaluria (PH), a rare pediatric genetic disease, which causes the liver to produce excess amounts of oxalate. The estimated U.S. population for PH is in the range of 1,000 patients.
Axium will be working in conjunction with OxThera and the Mayo Clinic in this Phase III clinical trial. “We are excited about the opportunity to be working with OxThera in the drug management of their Phase III clinical trial for Oxabact. It will also be an honor working on this project with the prestigious Mayo Clinic,” said Mark Montgomery, President & CEO of Axium.
Jon Heimer, President of OxThera, said, “OxThera is very excited about entering into Phase III studies with Oxabact™ in the U.S. and look forward to collaborating with Axium Healthcare Pharmacy for the important process of drug management.”
About Axium Healthcare Pharmacy:
Axium Healthcare Pharmacy, Inc. is a nationwide clinical specialty pharmacy provider with expertise in managing patients on complex therapies and specialty medication distribution. As one of the nation's leading specialty pharmacies, Axium Healthcare Pharmacy, Inc. provides comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, Growth Hormone Deficiency plus others. For more information, contact Axium Healthcare Pharmacy at 888.315.3395; by email info@axiumhealthcare.com
About OxThera:
OxThera is a clinical stage biotechnology company with its first product in Phase III. The company is based in Sweden (Uppsala) and Florida (Gainesville). The company develops products, based on its cell- and enzyme based proprietary technologies, for metabolic disorders based on excess oxalate from endogenous and exogenous sources. OxThera will market and sell its orphan drug products to treat and prevent hyperoxaluria and kidney stones in indications such as Primary and Enteric Hyperoxaluria. For more information, contact OxThera at (386) 418-1428; by email info@oxthera.com.
Contact: Valerie Thomas
Corporate Director of Marketing
(888) 315-3395
Valerie.thomas@axiumhealthcare.com
###
Contact
Axium Healthcare Pharmacy, Inc.
Valerie Thomas
8883153395
www.axiumhealthcare.com
Valerie Thomas
8883153395
www.axiumhealthcare.com
Contact
Categories